Breaking News Instant updates and real-time market news.

INCY

Incyte

$66.69

-0.3 (-0.45%)

12:45
05/17/18
05/17
12:45
05/17/18
12:45

Incyte has a conference call hosted by JPMorgan

JPMorgan Analyst Kasimov will host a conference call with CEO Herve Hoppenot on May 17 at 1 pm.

  • 17

    May

  • 12

    Jun

INCY Incyte
$66.69

-0.3 (-0.45%)

04/26/18
PIPR
04/26/18
NO CHANGE
Target $125
PIPR
Overweight
Nektar data at ASCO to confirm already positive data, says Piper Jaffray
Following Incyte's (INCY) epacadostat failure and the recent, "relatively underwhelming" Bristol-Myers (BMY) lung cancer dataset, there has been a negative shift in investor sentiment towards pure immuno-oncology combination approaches, Piper Jaffray analyst Tyler Van Buren tells investors in a research note. The analyst believes there is now increased scrutiny towards uncontrolled trials with low patient numbers, and thinks investors will require a more significant margin of improvement when compared to standard of care until definitively proven in Phase III. As such, he expects investors to be increasingly critical of early IO combination data. Nevertheless, he continues to believe that Nektar Therapeutics' (NKTR) NKTR-214 data at ASCO in early June will be "confirmatory of the already positive data in existing tumor types and supportive of new indications." He keeps an Overweight rating on Nektar shares with a $125 price target.
04/24/18
WBLR
04/24/18
NO CHANGE
WBLR
Incyte may trade flat or slightly up on panel outcome, says William Blair
William Blair analyst Y. Katherine Xu views yesterday's FDA panel, supporting approval of baricitinib at the 2 mg dose but voting against the 4 mg dose, as largely in line with expectations given the doubts raised in the briefing documents and during the panel discussion. Based on the panel's recommendation, the analyst maintains her 90% probability of success for baricitinib 2 mg to be approved in the United States by its action date in June. While an approval will be positive, the narrower label and restriction to the lower dose may limit baricitinib's market share, Xu tells investors in a research note. She believes Incyte (INCY) shares may trade flat or slightly positive on this outcome. The stock in premarket trading us down 4% to $65.60. Xu views the baricitinib panel outcome as a "slight net positive" to upadacitinib of AbbVie (ABBV).
04/24/18
JMPS
04/24/18
NO CHANGE
JMPS
JMP says baricitinib represents 'relatively small' part of Incyte value
After the majority of an FDA advisory committee members voted that the 2mg dose of baricitinib demonstrated efficacy and had a cleaner safety profile compared to the higher dose and also voted against recommending approval of the 4mg dose, JMP Securities analyst Liisa Bayko said she believes the 4mg dose of baricitinib "has a bleak future." However, she said the value of baricitinib is a "relatively small" part of the overall value of Incyte shares. Bayko, who previously had an Outperform rating and $145 price target on Incyte, noted that her rating and price target remain under review.
04/23/18
RBCM
04/23/18
NO CHANGE
RBCM
Outperform
Incyte AdCom meeting going more favorably than docs suggested, says RBC Capital
RBC Capital analyst Brian Abrahams said the FDA advisory committee meeting for baricitinib, a rheumatoid arthritis treatment developed by Incyte (INCY) and submitted for review by Eli Lilly (LLY), seems "considerably less negative" than the briefing documents for the meeting had suggested. He sees the tone of the panel and the panelist Q&A suggesting a high likelihood that baricitinib will be approved, with the potential still existing that even a 4mg version could be approved in some form. Abrahams has an Outperform rating and $75 price target on Incyte shares.

TODAY'S FREE FLY STORIES

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
09/19/18
09/19
14:16
09/19/18
14:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPOT

Spotify

$169.33

-6.1 (-3.48%)

14:16
09/19/18
09/19
14:16
09/19/18
14:16
Periodicals
Spotify accused of ' fostering a negative work culture for women,' Verge says »

Music streaming company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BABA

Alibaba

$162.49

5.85 (3.73%)

14:13
09/19/18
09/19
14:13
09/19/18
14:13
Periodicals
Alibaba no longer plans to bring 1M jobs to U.S. in wake of trade war, CNBC says »

Alibaba founder and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

SAFM

Sanderson Farms

$100.90

-2.04 (-1.98%)

14:09
09/19/18
09/19
14:09
09/19/18
14:09
Hot Stocks
Sanderson Farms reports on impact to operations from Hurricane Florence »

Sanderson Farms reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Oct

  • 06

    Nov

14:08
09/19/18
09/19
14:08
09/19/18
14:08
Conference/Events
RBC Capital internet analyst to hold a luncheon »

Internet Analyst Mahaney…

14:06
09/19/18
09/19
14:06
09/19/18
14:06
Conference/Events
RBC Capital multi-industry analyst to hold group luncheon »

Multi-Industry Analyst…

14:04
09/19/18
09/19
14:04
09/19/18
14:04
Conference/Events
RBC Capital biotech analysts to hold a group breakfast »

Biotech Gene Therapy…

CZR

Caesars

$10.90

0.1 (0.93%)

14:00
09/19/18
09/19
14:00
09/19/18
14:00
Options
Caesars option volume is 2X daily average and calls lead puts 10:1 »

Caesars option volume is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ELAN

Elanco

$0.00

(0.00%)

, LLY

Eli Lilly

$105.83

-1.06 (-0.99%)

13:51
09/19/18
09/19
13:51
09/19/18
13:51
Initiation
Elanco, Eli Lilly initiated  »

Elanco initiated with a…

ELAN

Elanco

$0.00

(0.00%)

LLY

Eli Lilly

$105.83

-1.06 (-0.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

  • 01

    Oct

  • 04

    Oct

  • 20

    Sep

LFUS

Littelfuse

$204.06

-9.68 (-4.53%)

13:41
09/19/18
09/19
13:41
09/19/18
13:41
Recommendations
Littelfuse analyst commentary  »

Use weakness to buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Sep

MRK

Merck

$70.16

-0.26 (-0.37%)

, BMY

Bristol-Myers

$60.93

-0.55 (-0.89%)

13:36
09/19/18
09/19
13:36
09/19/18
13:36
Periodicals
Merck cuts key cancer drug price for China launch, Caixin reports »

Merck (MRK) will cut the…

MRK

Merck

$70.16

-0.26 (-0.37%)

BMY

Bristol-Myers

$60.93

-0.55 (-0.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 22

    Oct

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 11

    Jan

  • 16

    Feb

GLUU

Glu Mobile

$7.30

-0.285 (-3.76%)

13:35
09/19/18
09/19
13:35
09/19/18
13:35
Options
Glu Mobile put volume heavy and directionally bearish »

Bearish flow noted in Glu…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REV

Revlon

$23.75

0.5 (2.15%)

, TLRY

Tilray

$227.50

72.51 (46.78%)

13:34
09/19/18
09/19
13:34
09/19/18
13:34
Periodicals
Revlon could be set for short squeeze similar to Tilray's, Mox Reports says »

Mox Reports, which has…

REV

Revlon

$23.75

0.5 (2.15%)

TLRY

Tilray

$227.50

72.51 (46.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TTWO

Take-Two

$129.93

-2.76 (-2.08%)

, SNE

Sony

$59.02

-0.8 (-1.34%)

13:32
09/19/18
09/19
13:32
09/19/18
13:32
Hot Stocks
Take-Two's Rockstar announces 'Red Dead Online' »

Take-Two's (TTWO)…

TTWO

Take-Two

$129.93

-2.76 (-2.08%)

SNE

Sony

$59.02

-0.8 (-1.34%)

MSFT

Microsoft

$111.22

-2.02 (-1.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 21

    Oct

  • 28

    Oct

  • 28

    Nov

  • 03

    Mar

13:30
09/19/18
09/19
13:30
09/19/18
13:30
General news
Hurricane Florence »

Hurricane Florence has…

13:30
09/19/18
09/19
13:30
09/19/18
13:30
General news
U.S. equities remain mixed with the Dow up »

U.S. equities remain…

AMZN

Amazon.com

$1,913.86

-27.34 (-1.41%)

13:29
09/19/18
09/19
13:29
09/19/18
13:29
Technical Analysis
Technical Take: Amazon.com attempting to bounce off third support test »

The shares are down over…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HEAR

Turtle Beach

$19.61

1.86 (10.48%)

13:25
09/19/18
09/19
13:25
09/19/18
13:25
Options
Turtle Beach call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WCN

Waste Connections

$79.49

-0.695 (-0.87%)

13:25
09/19/18
09/19
13:25
09/19/18
13:25
Conference/Events
Waste Connections participates in a conference call with UBS »

Analyst Windham holds a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
09/19/18
09/19
13:17
09/19/18
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
09/19/18
09/19
13:16
09/19/18
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DRI

Darden

$117.54

-1.39 (-1.17%)

13:10
09/19/18
09/19
13:10
09/19/18
13:10
Options
Darden Restaurants with a bullish option play ahead of earnings »

Darden Restaurants with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 20

    Sep

  • 11

    Oct

SSNLF

Samsung

$0.00

(0.00%)

13:09
09/19/18
09/19
13:09
09/19/18
13:09
Periodicals
Samsung may be working on 5G variant of Galaxy 10, XDA-Developers says »

Samsung may be planning…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDXG

MiMedx

$5.39

0.11 (2.08%)

13:05
09/19/18
09/19
13:05
09/19/18
13:05
Options
MiMedx call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Oct

AMZN

Amazon.com

$1,908.70

-32.5 (-1.67%)

, SFIX

Stitch Fix

$45.19

-5.295 (-10.49%)

12:55
09/19/18
09/19
12:55
09/19/18
12:55
Hot Stocks
Online retailers slide as Amazon reportedly testing recommendation service »

Shares of several…

AMZN

Amazon.com

$1,908.70

-32.5 (-1.67%)

SFIX

Stitch Fix

$45.19

-5.295 (-10.49%)

WMT

Walmart

$95.58

0.15 (0.16%)

FB

Facebook

$161.05

0.74 (0.46%)

W

Wayfair

$136.31

-6.92 (-4.83%)

WSM

Williams-Sonoma

$66.04

-1.3 (-1.93%)

SHOO

Steven Madden

$57.00

-0.7 (-1.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 01

    Oct

  • 28

    Oct

  • 15

    Nov

  • 03

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.